Browse Prior Art Database

Crystalline Form of N-(2-(4-(4-fluorobenzylcarbamoyl) -5-hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl) -5-methyl-1,3,4-oxadiazole-2- carboxamide

IP.com Disclosure Number: IPCOM000200598D
Publication Date: 2010-Oct-20
Document File: 2 page(s) / 79K

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a PDF file.
This is the abbreviated version, containing approximately 66% of the total text.

Page 01 of 2

Crystalline Form of N-(2-(4-(4-fluorobenzylcarbamoyl) -5-hydroxy-1-methyl-6- oxo-1, 6-dihydropyrimidin-2-yl)propan-2-yl) -5-methyl-1,3,4-oxadiazole-2- carboxamide
N-(2-(4-(4-fluorobenzylcarbamoyl) -5-hydroxy-1-methyl-6-oxo-1, 6-dihydropyrimidin-2- yl)propan-2-yl) -5-methyl-1,3,4-oxadiazole-2- carboxamide is known as RLT free hydroxy. RLT free hydroxy of the following chemical structure:

O

OH

F

N

N

N

H

N

O

H

N

O

N

O

is an antiretroviral drug used to treat HIV infection.

   Crystalline form A3 of RLT free hydroxy was found and described herein. Crystalline form A3 of RLT free hydroxy is characterized by data selected from: X-ray powder diffraction ("XRPD") peaks at: 7.8, 11.8, 15.5, 16.3, 23.3 and 28.5± 0.2 degrees two-theta; an XRPD pattern as depicted in figure 1; and combinations thereof.

Figure 1: XRPD of Crystalline Form A3 of RLT free hydroxy

Counts

RLT-ST-861

60000

40000

20000

0

10 20 30

Position [°2Theta] (Copper (Cu))

Counts

   Crystalline Form A3 of RLT free hydroxy may be further characterized by the X-ray powder diffraction pattern having additional peaks at 13.5, 18.4, 22.0, 25.1, and 26.7degrees two theta ±
0.2 degrees two theta.

   The x-ray powder diffraction was performed on a Scintag X-ray powder diffractometer model X'TRA, with a Cu-tube solid-state detector, round standard aluminum sample holder with

1


Page 02 of 2

round zero background quartz plate with cavity of 25 (diameter)*0.5 (dept.) mm. Copper Kα1

radiation (λ=1.5418 Å) was used. The scan...